{ "@context": "https://schema.org", "@type": "Service", "name": "Precision Medicine & Clinical Testing", "provider": { "@type": "Organization", "name": "GBiowit" }, "description": "Patient‑derived organoid drug sensitivity testing for personalized cancer treatment guidance." }
Message Top

Precision Medicine & Clinical Testing

Patient-derived organoid drug sensitivity testing for personalized cancer treatment guidance — CLIA-aligned workflows with rapid turnaround.

Transform Cancer Treatment with PDO Drug Testing

Using tumor tissue from individual patients, we screen chemotherapeutic and targeted agents to identify the most effective regimens before administration — reducing trial-and-error and improving patient outcomes.

Clinical PDO Establishment

Tissue processing within 24 hours of collection; clinical-grade organoid establishment with documented chain of custody; success rate monitoring.

Drug Sensitivity Profiling

Testing against standard-of-care chemotherapeutics, targeted agents, and emerging therapies; 5-8 concurrent regimens per patient; 2-3 week TAT.

Immunotherapy Assessment

Checkpoint inhibitor response prediction; CAR-T cell co-culture assays; tumor-infiltrating lymphocyte interaction studies.

Companion Diagnostic Support

Biomarker-organoid response correlation studies; predictive signature development; regulatory documentation support for CDx programs.

Combination Therapy Screening

Targeted + chemotherapy combinations; dual-targeted regimens; immunotherapy + targeted therapy evaluation based on clinical guidelines.

Clinical Decision Support

Ranked treatment recommendations with sensitivity scores; clinical report formatted for tumor board review; physician consultation available.

Clinical Workflow

1

Tumor Collection

Surgical resection or biopsy specimen received; pathological review; tissue allocation.

2

PDO Establishment

7-14 days for organoid line establishment; QC authentication; passage for screening.

3

Drug Screening

5-8 standard and targeted regimens tested in triplicate; positive/negative controls included.

4

Sensitivity Analysis

IC50 and AUC calculation; relative sensitivity ranking; statistical significance testing.

5

Clinical Report

Formatted report with ranked recommendations; sensitivity heatmap; delivered 14-21 days from receipt.

Clinical Applications

  • Refractory and recurrent cancer treatment guidance
  • Neoadjuvant and adjuvant therapy selection
  • Clinical trial enrollment stratification
  • Companion diagnostic development
  • Tumor board decision support
  • Treatment monitoring and resistance detection

Empower Your Clinical Decisions

Contact us to discuss how PDO drug sensitivity testing can guide therapy selection for your patients.

Get in Touch